Candel Therapeutics (NASDAQ:CADL – Free Report) had its price objective decreased by Canaccord Genuity Group from $25.00 to $13.00 in a research report sent to investors on Friday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.
CADL has been the subject of several other reports. UBS Group reiterated a “buy” rating on shares of Candel Therapeutics in a research note on Monday, August 17th. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Jefferies Financial Group assumed coverage on Candel Therapeutics in a research note on Thursday, October 22nd. They issued a “buy” rating and a $25.00 price target on the stock. Zacks Research downgraded Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a report on Thursday, October 15th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.57.
Read Our Latest Research Report on CADL
Candel Therapeutics Trading Down 26.1%
Candel Therapeutics stock opened at $6.20 on Friday. Candel Therapeutics has a 52 week low of $4.35 and a 52 week high of $14.00. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09. The stock has a market capitalization of $474.42 million, a P/E ratio of -4.19 and a beta of -0.27. The stock has a 50-day simple moving average of $9.75 and a 200 day simple moving average of $8.39.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06. Analysts expect that Candel Therapeutics will post -1.29 earnings per share for the current year.
Insider Buying and Selling
In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the transaction, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at $922,380. This represents a 8.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 14.30% of the company’s stock.
Institutional Investors Weigh In On Candel Therapeutics
Institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Candel Therapeutics in the second quarter valued at approximately $51,181,000. Bank of America Corp DE acquired a new stake in Candel Therapeutics during the 2nd quarter worth approximately $2,873,000. Wellington Management Group LLP acquired a new stake in Candel Therapeutics during the 2nd quarter worth approximately $2,119,000. Bank of New York Mellon Corp bought a new stake in Candel Therapeutics in the 2nd quarter valued at $1,975,000. Finally, Janus Henderson Group PLC bought a new stake in Candel Therapeutics in the 1st quarter valued at $845,000. Institutional investors own 13.93% of the company’s stock.
Candel Therapeutics News Roundup
These are some of the CADL news items that stood out recently:
- Positive Sentiment: Candel reported a third-quarter loss of $0.28 per share, narrower than analysts’ expected loss of $0.34. Third-quarter results and corporate update
- Negative Sentiment: The company now expects to submit its biologics license application for aglatimagene in mid-2027. The delay followed FDA discussions and pushed back a key potential catalyst, prompting sharp selling. Mid-2027 BLA plan
- Negative Sentiment: Reports also cited a wider operating loss, adding to concerns as investors reassess the company’s timeline and financial outlook. Operating loss and FDA discussion
Candel Therapeutics Company Profile
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Further Reading
- Five stocks we like better than Candel Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
